Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
276.19
+2.09 (0.76%)
At close: Jun 6, 2025, 4:00 PM
278.83
+2.64 (0.96%)
After-hours: Jun 6, 2025, 7:14 PM EDT
Madrigal Pharmaceuticals Employees
Madrigal Pharmaceuticals had 528 employees as of December 31, 2024. The number of employees increased by 152 or 40.43% compared to the previous year.
Employees
528
Change (1Y)
152
Growth (1Y)
40.43%
Revenue / Employee
$601,104
Profits / Employee
-$741,646
Market Cap
6.13B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
MDGL News
- 4 days ago - Madrigal Pharmaceuticals to Participate in the 46th Annual Global Goldman Sachs Health Care Conference - GlobeNewsWire
- 20 days ago - In Search Of A Tailwind, Sailing The Doldrums With Madrigal Pharmaceuticals - Seeking Alpha
- 27 days ago - Madrigal Announces New Clinical Data Demonstrating Rezdiffra™ (resmetirom) Significantly Improved Multiple Noninvasive Tests and Portal Hypertension Risk in Patients with Compensated MASH Cirrhosis - GlobeNewsWire
- 4 weeks ago - Madrigal Pharmaceuticals: An Encouraging Start For Rezdiffra - Seeking Alpha
- 5 weeks ago - Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 5 weeks ago - Madrigal to Present Late-Breaking Resmetirom Data in Patients with Compensated MASH Cirrhosis at the EASL Congress - GlobeNewsWire
- 7 weeks ago - Madrigal Pharmaceuticals to Release First-Quarter 2025 Financial Results and Host Webcast on May 1, 2025 - GlobeNewsWire